Thomas K. Equels net worth and biography

Thomas Equels Biography and Net Worth

CEO of AIM ImmunoTech

THOMAS K. EQUELS, Esq., has been a Director and serves as our Executive Vice Chairman (since 2008), Chief Executive Officer (since 2016) and President (since 2015). Mr. Equels is the owner of and former President and Managing Director of the Equels Law Firm headquartered in Miami, Florida that focuses on litigation. For over a quarter century, Mr. Equels has represented national and state governments as well as companies in the banking, insurance, aviation, pharmaceutical and construction industries. Mr. Equels received his Juris Doctor degree with high honors from Florida State University. He is a summa cum laude graduate of Troy University and also obtained his Masters’ Degree from Troy. He is a member of the Florida Bar Association and the American Bar Association.

What is Thomas K. Equels' net worth?: The estimated net worth of Thomas K. Equels is at least $9.96 thousand as of April 4th, 2025. Mr. Equels owns 19,008 shares of AIM ImmunoTech stock worth more than $9,960 as of April 11th. This net worth estimate does not reflect any other investments that Mr. Equels may own. Learn More about Thomas K. Equels' net worth.
How do I contact Thomas K. Equels?: The corporate mailing address for Mr. Equels and other AIM ImmunoTech executives is 2117 SW HIGHWAY 484, OCALA FL, 34473. AIM ImmunoTech can also be reached via phone at (352) 448-7797 and via email at [email protected]. Learn More on Thomas K. Equels' contact information.
Has Thomas K. Equels been buying or selling shares of AIM ImmunoTech?: Thomas K. Equels has not been actively trading shares of AIM ImmunoTech during the last ninety days. Learn More on Thomas K. Equels' trading history.
Who are AIM ImmunoTech's active insiders?: AIM ImmunoTech's insider roster includes Nancy Bryan (Director), Thomas Equels (CEO), and Peter Rodino, III (COO, Executive Director for Governmental Relations, General Counsel, Secretary). Learn More on AIM ImmunoTech's active insiders.

Thomas K. Equels Insider Trading History at AIM ImmunoTech

Thomas K. Equels Buying and Selling Activity at AIM ImmunoTech

AIM ImmunoTech Company Overview

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Today's Range

Now: $0.52

$0.51

$0.55

50 Day Range

MA: $0.85

$0.52

$1.25

2 Week Range

Now: $0.52

$0.51

$20.35

Volume

170,123 shs

Average Volume

9,899,032 shs

Market Capitalization

$4.27 million

P/E Ratio

N/A

Dividend Yield